Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

被引:44
|
作者
Poettgen, Christoph [1 ]
Theegarten, Dirk [5 ]
Eberhardt, Wilfried [2 ]
Levegruen, Sabine [1 ]
Gauler, Thomas [2 ]
Krbek, Thomas
Stamatis, Georgios [6 ]
Teschler, Helmut [7 ]
Kuehl, Hilmar [3 ]
Bockisch, Andreas [4 ]
Stuschke, Martin [1 ]
机构
[1] Univ Duisburg Essen, Dept Radiotherapy, DE-45122 Essen, Germany
[2] Univ Duisburg Essen, Dept Intenal Med Canc Res, DE-45122 Essen, Germany
[3] Univ Duisburg Essen, Dept Diagnost & Intervent Radiol, DE-45122 Essen, Germany
[4] Univ Duisburg Essen, Dept Nucl Med, DE-45122 Essen, Germany
[5] Univ Duisburg Essen, Inst Pathol & Neuropathol, DE-45122 Essen, Germany
[6] Univ Duisburg Essen, Dept Thorac Surg, DE-45122 Essen, Germany
[7] Univ Duisburg Essen, Dept Pulmonol, DE-45122 Essen, Germany
关键词
chemoradiotherapy; dual-modality PET/CT; locally advanced non-small cell lung cancer; macrophage infiltration; neoadjuvant;
D O I
10.1159/000134474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods: F-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/ 45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4-9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV > 2.5 and volumes larger than the median (7.9 cm(3)) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 50 条
  • [1] FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology
    Ryu, JS
    Choi, NC
    Fischman, AJ
    Lynch, TJ
    Mathisen, DJ
    LUNG CANCER, 2002, 35 (02) : 179 - 187
  • [2] Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
    Yuka Yamamoto
    Yoshihiro Nishiyama
    Toshihide Monden
    Yasuhiro Sasakawa
    Motoomi Ohkawa
    Masashi Gotoh
    Kotaro Kameyama
    Reiji Haba
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 140 - 147
  • [3] Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
    Yamamoto, Y
    Nishiyama, Y
    Monden, T
    Sasakawa, Y
    Ohkawa, M
    Gotoh, M
    Kameyama, K
    Haba, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (02) : 140 - 147
  • [4] Neoadjuvant therapy for resectable non-small cell lung cancer
    Welcker, Katrin
    Jonigk, Danny
    Kropf-Sanchen, Cornelia
    Tufman, Amanda
    Draube, Andreas
    Stenzinger, Albrecht
    Zaatar, Mohamed
    Thomas, Michael
    PNEUMOLOGIE, 2025, 79 (01): : 16 - 24
  • [5] Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy
    Liu-Jarin, XL
    Stoopler, MB
    Raftopoulos, H
    Ginsburg, M
    Gorenstein, L
    Borczuk, AC
    MODERN PATHOLOGY, 2003, 16 (11) : 1102 - 1108
  • [6] Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
    Kalvapudi, Sukumar
    Vedire, Yeshwanth
    Yendamuri, Sai
    Barbi, Joseph
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Comparison of Diagnostic Performance of Preoperative PET-CT for Patients with and without Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Does Induction Therapy Affect the Preoperative PET-CT Results?
    Gursoy, Soner
    Ucvet, Ahmet
    Erbaycu, Ahmet E.
    Yamansavci, Esra
    Koparal, Hakan
    Ozbilek, Engin
    Kaya, Seyda O.
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (03): : 143 - 152
  • [8] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [9] Restaging after induction therapy for non-small cell lung cancer
    Van Schil, P
    New Advances in Thoracic Oncology: From Scientific Evidence to Optimal Management, 2005, 350 : 27 - 35
  • [10] Docetaxel in neoadjuvant therapy of early-stage non-small cell lung cancer
    Betticher, DC
    ONKOLOGIE, 2003, 26 : 33 - 36